BioWorld

March 25, 2002

Gilead Files NDA For Hepatitis B Product, Seeks Priority Review

Gilead Sciences Inc. on Thursday filed a new drug application with the FDA for a hepatitis B drug expected to capture a sizeable portion of the market. (BioWorld Today) Read More

NeuroSearch, Grupo Ferrer Drop GABA Anxiety Drug In Phase I

Princeton Team Blows E. coli’s Cover, Reveals Germ’s Biofilm Formation, Predicts Antibiotics

House Committee Pursues ImClone, Wants Family Contacts

Other News To Note

Aphton Sells 1.2M Shares, Raises $12.6M For Trials, Operations

Quarterly Earnings Reports

Today's news in brief

BioWorld

BioWorld briefs for Jan 26, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 23, 2026.

Illustration of magnifying glass inspecting brain

Neurotrimin unveiled as marker in intellectual disability

BioWorld Science

Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Illustration of human body surrounded by DNA, cell and drug icons

Cell/gene therapy sector now sustainable; China competition mounting

BioWorld

There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...